Shares of Apyx Medical Corporation (NASDAQ:APYX – Get Free Report) have been given an average recommendation of “Moderate Buy” by the eight brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $6.50.
Several research firms have commented on APYX. HC Wainwright began coverage on shares of Apyx Medical in a research report on Monday, July 13th. They set a “buy” rating and a $7.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a report on Monday, September 21st. Zacks Research upgraded Apyx Medical to a “hold” rating in a report on Tuesday, July 14th. Finally, Maxim Group initiated coverage on Apyx Medical in a research report on Tuesday. They issued a “buy” rating and a $6.00 price objective on the stock.
Get Our Latest Stock Report on Apyx Medical
Apyx Medical Trading Up 4.0%
Apyx Medical (NASDAQ:APYX – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. The business had revenue of $13.88 million for the quarter, compared to analysts’ expectations of $13.18 million. Apyx Medical had a negative return on equity of 76.60% and a negative net margin of 14.78%. On average, sell-side analysts anticipate that Apyx Medical will post -0.25 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Apyx Medical
A number of hedge funds have recently made changes to their positions in the business. Nwam LLC grew its position in shares of Apyx Medical by 35.0% during the 2nd quarter. Nwam LLC now owns 17,239 shares of the company’s stock valued at $77,000 after acquiring an additional 4,467 shares during the period. Silverberg Bernstein Capital Management LLC lifted its stake in Apyx Medical by 0.8% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 1,041,070 shares of the company’s stock valued at $3,842,000 after purchasing an additional 8,067 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Apyx Medical during the second quarter valued at $62,000. AXQ Capital LP bought a new position in Apyx Medical during the second quarter valued at $78,000. Finally, Jefferies Financial Group Inc. purchased a new stake in Apyx Medical in the second quarter worth $110,000. 55.33% of the stock is currently owned by institutional investors.
Apyx Medical Company Profile
Apyx Medical Corporation (NASDAQ: APYX) is a medical technology company that develops, manufactures and markets energy-based surgical products. The company focuses on systems that use its proprietary Helium Plasma technology to support tissue cutting, coagulation and soft-tissue procedures.
Apyx Medical’s product portfolio includes the Renuvion system, which is used in surgical and aesthetic procedures, and J-Plasma, an earlier generation of its Helium Plasma technology. Its products are marketed for use in fields such as plastic and cosmetic surgery, general surgery and other soft-tissue applications.
The company was formerly known as Bovie Medical Corporation and adopted the Apyx Medical name in 2018.
Featured Stories
- Five stocks we like better than Apyx Medical
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.
